Cirrhosis is characterized by muscle wasting, malnutrition, and functional decline that confer excess mortality not well quantified by the Model for End-Stage Liver Disease (MELD) Sodium (MELDNa) score. We aimed to develop a frailty index to capture these extrahepatic complications of cirrhosis and enhance mortality prediction in patients with cirrhosis. Consecutive outpatients listed for liver transplantation at a single transplant center without MELD exceptions were assessed with candidate frailty measures. Best subset selection analyses with Cox regression identified subsets of frailty measures that predicted waitlist mortality (5death or delisting because of sickness). We selected the frailty index by balancing statistical accuracy with clinical utility. The net reclassification index (NRI) evaluated the %patients correctly reclassified by adding the frailty index to MELDNa. Included were 536 patients with cirrhosis with median MELDNa of 18. One hundred seven (20%) died/were delisted. The final frailty index consisted of: grip strength, chair stands, and balance. The ability of MELDNa and the frailty index to correctly rank patients according to their 3-month waitlist mortality risk (i.e., concordance-statistic) was 0.80 and 0.76, respectively, but 0.82 for MELDNa1frailty index together. Compared with MELDNa alone, MELDNa1frailty index correctly reclassified 16% of deaths/delistings (P 5 0.005) and 3% of nondeaths/delistings (P 5 0.17) with a total NRI of 19% (P < 0.001). Compared to those with robust frailty index scores (<20th percentile), cirrhotics with poor frailty index scores (>80th percentile) were more impaired by gait speed, difficulty with Instrumental Activities of Daily Living, exhaustion, and low physical activity (P < 0.001 for each). Conclusion: Our frailty index for patients with cirrhosis, comprised of three performance-based metrics, has construct validity for the concept of frailty and improves risk prediction of waitlist mortality over MELDNa alone. (HEPATOLOGY 2017;66:564-574).
C irrhosis is the terminal complication of a multitude of chronic liver conditions that lead to progressive liver failure and, ultimately, death. The most commonly used metric to determine prognosis for patients with cirrhosis is the Model for End Stage Liver Disease (MELDNa) score. Comprised of a logarithmic combination of serum total bilirubin, creatinine, international normalized ratio (INR) for prothrombin time, and sodium the MELDNa score can accurately predict 90-day mortality for most patients with cirrhosis. (1) What these blood tests fail to capture, however, are the effects of muscle wasting, Abbreviations: ADLs, activities of daily living; AIC, Aikaike information criterion; BMI, body mass index; C-statistic, concordance-statistic; CHC, chronic hepatitis C; 95% CIs, 95% confidence intervals; ESLD, end-stage liver disease; FrAILT, Functional Assessment in Liver Transplantation; HE, hepatic encephalopathy; IADLs, instrumental ADLs; INR, international normalized ratio; IQR, interquartile range; LT, liver transplantation; MELD, Model for End-Stage Liver Disease; MELDNa, Model for End-Stage Liver Disease Sodium; NASH, nonalcoholic steatohepatitis; NRI, net reclassification index; UCSF, University of California-San Francisco; UNOS, United Network for Organ Sharing.
undernutrition, and functional decline that are nearly universal findings in decompensated patients with cirrhosis and contribute to excess mortality in this population. (2) We have sought to objectively measure "physical frailty"-a term that we believe embodies these extrahepatic manifestations of cirrhosis-in patients with end-stage liver disease (ESLD) and quantify its impact on health-related outcomes. In the field of geriatrics, frailty has been commonly defined as a distinct biological condition of increased vulnerability to health stressors (3) and operationalized using a number of instruments such as the Fried Frailty Index (3) and Short Physical Performance Battery. (4) The individual components of these instruments (e.g., hand grip strength, depression scale, and short gait speed) have the strong advantage of being easy to administer at baseline and longitudinally at the bedside, even in patients with cirrhosis. (2, 5) However, these measures were originally developed in cohorts of community-dwelling adults over age 65 years without known liver disease. As a result, their true discriminative ability for mortality in patients with cirrhosis is unknown. Furthermore, the components of the frail phenotype may differ between patients with and without cirrhosis. For example, sarcopenia may play a greater role in physical frailty in a patient with ESLD compared to an older adult with normal hepatic synthetic function. On the other hand, decreased cardiopulmonary reserve may contribute more to the frail phenotype in the 90-year-old adult without liver disease than in a frail 60-year-old patient with cirrhosis.
Therefore, in this study, we aimed to develop a continuous and quantitative index of physical frailty based on readily available instruments that predict mortality for patients with cirrhosis.
Patients and Methods
This study included patients enrolled in the Functional Assessment in Liver Transplantation (FrAILT) Study from March 2012 until February 2016. The full study protocol is provided in (Supporting Table S1 ). The FrAILT Study, initiated in July 2012, is an ongoing study of adults (!18 years) with cirrhosis who are listed for liver transplantation (LT) at the University of California-San Francisco (UCSF) and are seen in the outpatient UCSF Transplant Hepatology clinic. To ensure an adequate number of events during followup, we prioritized consecutive recruitment of all patients with a laboratory MELD score !12. In September 2013, we relaxed our recruitment criteria to include all patients aged 60 years and older, regardless of laboratory MELD score, given the conceptual association between frailty and advancing age. Patients were excluded if they were listed with MELD exception points, because these patients have a trajectory to LT that is independent of hepatic decompensation. Although national liver allocation changed in January 2016 to be based on MELDNa rather than MELD, we maintained study inclusion criteria as MELD for consistency. Also excluded were those with severe hepatic encephalopathy (HE; n 5 8), as defined by the time to complete a Numbers Connection Test (6) of >120 seconds, because this may impair the patient's ability to provide informed consent and complete tests of physical function. Of those who met inclusion criteria, 97% enrolled in the FrAILT Study. (2, 5) Four subjects who refused to complete all study procedures (i.e., assessments of frailty) were excluded from the analyses.
At enrollment, all patients underwent the tests of physical frailty that have been commonly utilized in the geriatric literature (Table 1) . These measures included four performance-based tests (gait speed, grip
strength, chair stands, and balance) and five selfreported tests (unintentional weight loss, exhaustion, physical activity, activities of daily living [ADL] , and instrumental ADLs [IADLs]). All assessments were performed by one of two study personnel specifically trained at administering these study procedures in the same order and same manner for each study subject. On the same day as the clinic visit, the patient's hepatologist was asked to subjectively rate his or her patient's health using the following question:
"We are interested in your general impression about your patient's overall health, as compared to other patients with underlying liver disease. How would you rate this patient's overall health today? Excellent (0), very good (1), good (2), fair (3), poor (4), or very poor (5) ."
This rating was collected solely for the purposes of providing information regarding construct validity of the frailty measures. We have previously demonstrated that this subjective clinician assessment can identify LT candidates at high risk for waitlist mortality. (7) At the time of enrollment, demographic data were extracted from the clinic visit note from the same day as the physical frailty testing. Patients were classified as having hypertension or diabetes if listed in the past medical history or taking a medication to manage hypertension or diabetes. Ascites was ascertained from the physical examination or mention of ascites in the management plan. Laboratory data within 3 months of the frailty assessment were collected from the electronic health record. Candidate prognostic indicators were recorded in blind with respect to the primary endpoint. All patients were followed prospectively until their terminal waitlist event (e.g., death/delisting, LT) or, for those who had not experienced a terminal waitlist event, until February 2016. "Delisting for being too sick for LT" was decided by consensus among the LT team members if there was concern that an individual would not achieve acceptable outcomes post-LT because of medical comorbidities or current medical acuity. This decision was made independently of the frailty assessments performed for the study, because the results from the study assessments were not made available to the clinical care team. Outcomes (e.g., death, delisting, or transplant) were ascertained quarterly from UNetSM, the official online database for the United Network for Organ Sharing (UNOS). Per UNOS requirements, outcomes must be recorded into UNetSM within 24 hours of the outcome and therefore is a reliable source of information about the patients' current waitlist status. (3) Performance-based Meters/second Subjects were asked to walk 8 feet as quickly as they could. Patients unable to walk at all (i.e., wheelchair bound) were assigned a gait speed of 0.01 meters/second. Grip strength (3) Performance-based Kilogram This was measured in each subject's dominant hand using a hand dynamometer (Jamar Hydraulic hand dynanometer). We averaged three trials. Chair stands (4) Performance-based Number of chair stands per second
Number of chair stands completed in 30 seconds Balance (4) Performance-based Seconds Ability to balance in three positions (feet placed side to side, semitandem, and tandem) for 10 seconds each Unintentional weight loss (3) Self-report 0 5 no 1 5 yes Self-reported unintentional weight loss of !10 pounds in the last year Exhaustion (3) Self-report 0 5 no 1 5 yes
Identified by two self-reported questions from the Center for Epidmiologic Studies-Depression scale, as originally used in the Fried Frailty Index (3) Physical activity (3) Self-report Kilocalories per week The number of kilocalories expended per week is assessed using the self-reported Minnesota Leisure Time Activity Scale. ADLs (32) Self-report Maximum six activities Ability to perform basic activities of self-care without assistance (e.g., dressing, bathing, or toileting) IADs (33) Self-report Maximum eight activities Ability to perform activities to live within society without assistance (e.g., shopping, preparing meals, administering medications, and laundry)
STATISTICAL ANALYSIS
The primary outcome was time from first study assessment to waitlist mortality, defined as death pre-LT or delisting for being too sick for transplant. For the analyses, patients who underwent living donor LT were censored at the time of transplant because living donor surgery interrupts the natural trajectory of liver disease on the waitlist. Patients delisted for reasons other than being too sick (e.g., substance abuse, nonadherence) were censored at the time of waitlist removal.
Probability of waitlist mortality at 3, 6, and 12 months and 95% confidence intervals (95% CIs) were estimated using the Kaplan-Meier method. Univariable Cox regression assessed the association between covariables and waitlist mortality. The proportional hazards assumption was assessed by reviewing the survival function plots. Linearity of continuous variables was tested by adding quadratic terms to the model, and Loess plots were used to visualize the functional form of the variables. Given the inherent sex differences in grip strength (8) and walk speed (9) norms, we converted grip strength and walk speed into sexspecific z-scores for use in the prediction modeling:
Adjusted test for a woman The resulting z-score centers grip strength and walk speed around the sex-specific means and scales the variables to SD units away from the mean of each sex. In other words, women and men with a mean score for their respective sexes will have the same score of 0, whereas women and men with a grip strength value that is 1 SD above their sex mean will have the same score of 1.
We then proceeded to develop a frailty index intended for use in adult patients with cirrhosis awaiting LT in the outpatient setting. We used a combination of step-wise selection, Akaike information criteria (AIC) reduction, and best subset selection, developed by Shtatland et al., (10) to identify prediction models for waitlist mortality consisting of multiple permutations of the physical frailty instruments. First, step-wise selection using Cox regression (PROC PHREG, SELECTION5STEPWISE) identified the full stepwise sequence of potential models from the null model to the full model containing all explanatory variables, for a total of 10 candidate models. We calculated AIC for the 10 candidate models and identified the optimal number of explanatory variables (three to four variables) to include in the frailty index, indicated by the number of covariables in the model with the lowest AIC. To assess a broad spectrum of candidate models that were both predictive and feasible to perform in the clinical setting, we applied best subset selection (PROC PHREG, SELECTION5SCORE) to identify the five best models within and just beyond the optimal covariable range. Best subset selection uses the branch-and-bound algorithm (11) to rank models (i.e,, combinations of variables) in order of global score chisquare statistic. Given the optimal range of three to four explanatory variables, we assessed models with two covariables (most clinically feasible) to six covariables (potentially most predictive). In other words, we identified and evaluated the five best combinations of two-variable models, three-variable models, fourvariable models, five-variable models, and six-variable models, capturing a total of 25 candidate models. We selected the "best" models by balancing model accuracy with simplicity, using a combination of: (1) AIC to measure the relative quality of the models, where a lower AIC indicates higher model quality; (2) concordance statistic (C-statistic; with bootstrap 95% CIs), which evaluates the absolute discrimination of the model; and (3) ease of use in clinical practice, with an underlying assumption that a model including more variables is less clinically useful than a more parsimonious model. The final frailty index was calculated as:
where the coefficients are the parameter estimates directly estimated in the Cox regression model containing the components of the frailty index. To convert the index to a positive, rather than negative, scale, a constant was added to the equation to start the scale at a value of 1. We selected this approach-best subset selection combined with step-wise selection and AIC reduction-because this methodology is asymptotically equivalent to the commonly used internal validation methods, cross-validation, and bootstrap. This was critical because an external validation cohort, the preferred validation method, is not yet available. The disadvantage is that best subset selection methodology is not available for competing risk regression. (12) However, in our cohort, the estimates of waitlist mortality, our primary outcome, were similar at 3, 6, and 12 months (Supporting Table S2 ).
To evaluate the impact of the selected frailty index on improving prediction of MELDNa, we compared the proportion of patients whose risk of waitlist mortality at 3 and 12 months, estimated from the Cox model, was correctly reclassified using MELDNa versus MELDNa plus the frailty index using the net reclassification index (NRI). The NRI utilized a risk of waitlist mortality stratified by risk categories based on the cohort event rate and clinical relevance (13) at 3 months (<5%, 5%-10%, and !10%) and 12 months (<10%, 10%-15%, and !10%).
Statistical analyses were performed using SAS (v9.4; SAS Institute Inc., Cary, NC) and Stata software (v14; StataCorp LP, College Station, TX). The Institutional Review Board at the UCSF approved this study. This article adheres to the Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis Statement (Supporting Table S3 ). (14) Results
BASELINE CHARACTERISTICS, PHYSICAL FRAILTY SCORES, AND ASSOCIATIONS WITH WAITLIST MORTALITY
Baseline characteristics of the 536 patients enrolled in the FrAILT Study are shown in Table 2 . Median age of this cohort was 58 years and 41% were women. Over half (58%) self-identified as non-Hispanic white, 26% as Hispanic white, 3% black, and 5% Asian. Median height, weight, and body mass index (BMI) were 170 cm, 82 kg, and 28 kg/m 2 , respectively. The etiology of cirrhosis was alcoholic liver disease in 22%, chronic hepatitis C (CHC) in 40%, nonalcoholic steatohepatitis (NASH) in 14%, autoimmune/ cholestatic liver diseases in 14%, and "other" in 10%. Prevalence of hypertension was 39% and diabetes was 28%. Standard metrics of liver disease severity were assessed upon study enrollment (Table 2) . Median MELD score was 15, MELDNa was 18, and albumin was 3.0 g/dL. Four percent of the cohort had end-stage renal disease requiring hemodialysis. Ascites was present in a total of 34% of the cohort, and HE, defined as a numbers connection test time !60 seconds, was present in 20%. Median Child-Pugh score was 8. Table 3 presents a summary of the measures of physical frailty in the study cohort, along with available normative data for individuals in the general population of older adults without ESLD. With respect to performance-based characteristics: median walk speed for the FrAILT cohort was 1.2 meters per second, grip strength was 28 kg, number of chair stands per seconds was 0.4, and balance was 30 seconds. For the selfreported measures, 46% reported unintentional weight loss, 52% met criteria for exhaustion, and median kilocalories expended per week was 126. Median numbers of ADLs and IADLs that patients reported being able to perform independently were 6 and 8, respectively.
Median (interquartile range; IQR) follow-up time was 11 (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) months. By the end of follow-up, 107 (20%) died or were delisted for being too sick for transplant and 128 (24%) underwent deceased donor LT. The probability of waitlist mortality at 3, 6, and 12 months was 5% (95% CI, 3-7), 9% (95% CI, 6-12), and 15% (95% CI, 12-19), respectively. All baseline liver disease severity parameters were associated with waitlist mortality in univariable Cox regression: MELD/MELDNa score, serum total bilirubin, creatinine, INR, serum albumin, dialysis, ascites, HE, and Child Pugh score ( Table 2) . Eight of nine measures of physical frailty were significantly associated with waitlist mortality in univariable Cox regression; the only variable that did not show an association was selfreporting of unintentional weight loss (Table 2) .
DEVELOPING THE FRAILTY INDEX FOR PATIENTS WITH CIRRHOSIS
In Table 4 , we display seven candidate models for the frailty index, along with their AIC values and C-statistics. As a point of reference, in our cohort, the AIC and C-statistic (including all follow-up time) for MELDNa were 1,126 and 0.70, respectively. Model 2, which included grip strength, chair stands, and balance, and best balanced quality (AIC, 1,112) with accuracy (C-statistic, 0.72) with ease of use in clinical practice. Substituting walk speed for grip strength (model 3), in order to avoid the use of the hand dynanometer, resulted in a substantially higher AIC (1,117), indicating lower model quality. Adding variables to model 2 (models 4 through 7) did not meaningfully improve either the AIC (1,112-1,113 ) or C-statistic (0.72-0.73). Figure 1 shows the distribution of frailty index scores for the cohort. Higher frailty index scores indicate a higher degree of frailty. Compared to those with a frailty index score in the bottom 20th percentile ("robust"), patients with cirrhosis with a frailty index score in the top 80th percentile ("frail") were more impaired by median walk speed (0.8 vs. 1.5 m/sec; P < 0.001), ADLs (5 vs. 6; P < 0.001), IADLs (5 vs. 8; P < 0.001), low physical activity (31 vs. 0%; P < 0.001), and % meeting criteria for exhaustion (78 vs. 32%; P < 0.001). Furthermore, subjective clinician assessment scores (on a scale of 0-5 where 0 is robust) were significantly worse among patients who were frail versus not frail by the frailty index (3 vs. 2; P < 0.001).
PROGNOSTIC VALUE OF THE FRAILTY INDEX FOR PATIENTS WITH CIRRHOSIS
We then evaluated the ability of the frailty index to enhance risk prediction for waitlist mortality at 3 months over MELDNa alone. The ability of the MELDNa and the frailty index to correctly rank patients according to their 3-month risk of waitlist mortality (i.e., C-statistic) were 0.80 and 0.76, respectively. The combination of MELDNa and the frailty index together resulted in a C-statistic of 0.82 for 3-month waitlist mortality prediction. Compared with MELDNa alone, MELDNa1the frailty index correctly reclassified 16% of deaths/delistings (P 5 0.005) and 3% of nondeaths/nondelistings (P 5 0.17) for a total NRI of 19% (P < 0.001). The number of patients reclassified is shown in Table 5 . Patients who died/ were delisted who were correctly re-classified by MELDNa1the frailty index were older (62 vs. 54 years) and substantially more likely to be obese (59 vs. 41%), have hypertension (44 vs. 31%), diabetes (59 vs. 24%), end-stage renal disease (26 vs. 6%), or hepatic encephalopathy (89 vs. 46%; (Table 6) . This model was not among the highest performing models by AIC using best subset selection, but is included here to demonstrate performance characteristics of a performancebased model that does not require any specialized equipment for testing.
Finally, given the potential clinical utility of the frailty index in predicting outcomes over a longer term on the waitlist, we evaluated the prognostic performance of the frailty index at 12 months. The Cstatistics for prediction of 12-month risk of waitlist mortality was 0.73 for MELDNa and 0.73 for the frailty index alone, and the combination of MELDNa and the frailty index together resulted in a C-statistic of 0.77 at 12 months. Compared to MELDNa alone, the addition of the frailty index to MELDNa alone correctly reclassified 2% of deaths/delistings (P 5 0.72) and 17% of nondeaths/nondelistings (P < 0.001) for a total NRI of 19% (P 5 0.002).
Discussion
The MELD score has proven, time and time again, to predict mortality in patients with cirrhosis. (1, 15) However, clinicians have long recognized that, at a given MELD score, the clinical manifestations of patients with ESLD are highly heterogeneous. For example, at a MELD score of 15, one patient may have well-controlled ascites and be working full-time, whereas another patient may have refractory ascites, sarcopenia, and barely be able to stand on his or her own. On paper, these two patients have the same (relatively low) predicted probability of death based on their MELD score-and therefore the same (low) priority for LT-but any clinician will tell you that the latter patient clearly carries a higher risk of death. Yet, at the current time, we lack the tools to objectively capture this risk.
Here, we present a liver-specific frailty index that objectively captures this frail phenotype in patients with ESLD in the outpatient setting. Consisting of three simple, performance-based tests of physical frailty-grip strength, chair stands, and balance Interior cells reflect the number of patients within the predicted risk categories. Gray-shaded cells indicate patients with an increased predicted risk of waitlist death estimated by MELDNa 1 frailty index versus MELDNa alone. Cells that are outlined in black indicate patients with a decreased risk of death estimated by MELDNa 1 frailty index versus MELDNa alone. White cells (nonoutlined) with italicized text indicate no change in risk category when the frailty index is included in estimating risk.
testing-this index can feasibly be measured in the clinic setting at baseline and longitudinally. Furthermore, our analyses demonstrate that a frailty index can enhance risk prediction for waitlist mortality in patients with cirrhosis awaiting LT over MELDNa alone. This was particularly true for those who were older, obese, or had HE or medical comorbidities, risk factors that we would not expect to be adequately captured by total bilirubin, creatinine, INR, or sodium. For this reason, we intentionally did not adjust for these patient-related related factors because we believe that they contribute directly to the frail phenotype rather than act independently of it. The strength of a frailty index is that it allows us to measure the combined effect of all of these factors on one's physiological reserve. We have made this frailty index calculator available at: http://liverfrailtyindex.ucsf.edu. It is important to note the tradition of frailty instruments in the literature. All of the tests that we administered in our study have repeatedly demonstrated prognostic utility in geriatric populations (for whom they were originally established) (3, 4, 9, 16) -and more recently in nongeriatrics, (17, 18) surgical, (19, 20) and non-LT populations. (21) (22) (23) (24) This enduring history of frailty provides strong support for the broad applicability of these instruments to diverse populations. That an index consisting of a combination of these tests enhances mortality risk prediction in patients with ESLD awaiting LT builds upon this robust foundation of frailty in the literature.
How do we envision a frailty index to be incorporated into clinical practice? We do not intend for the frailty index to replace the MELD score. Given its strong prognostic value and sole reliance on common laboratory tests that are readily available, MELD plays an indispensable role in the national LT allocation system. Rather, the frailty index should serve to complement the MELD in our clinical decision making and facilitate discussions with patients. As an example of the impact that the frailty index might have on clinical decision making and management, we offer predicted probabilities of death for 4 hypothetical outpatients classified by MELDNa scores and frailty status based on our model (Fig. 2) . Patients with cirrhosis who display the frail phenotype experience a risk of waitlist mortality that exceeds that predicted by MELDNa alone. These frail patients should aggressively seek means to shorten their wait time (e.g., living donor LT, listing at centers with lower transplant MELDNa scores, or acceptance of higher-risk donor livers). For those who are not eligible for LT, frailty justifies initiation of palliative/hospice care and provides the catalyst for developing ESLD management programs targeting the most vulnerable. For all patients with cirrhosis, a firm "diagnosis" of frailty-which is potentially reversible through exercise and adequate nutrition-represents an opportunity for patients to gain control of their disease. There is nothing they can do about their MELDNa score, but the prospect of changing their frailty trajectory can offer them hope.
We acknowledge the following limitations to this study. We did not internally validate these results using a split-sample cohort, but rather utilized a combination of step-wise selection, AIC reduction, and best subset selection on the entire cohort to derive the frailty index. This was a deliberate choice, given that studies have demonstrated that this combination of selection methods is equivalent to cross-validation and bootstrapping and is preferred to internal validation. (10, 25) External validation, however, remains the gold standard to assess the true validity of this index when applied to other patient samples and is our next step. Whereas reproducibility of these measures has not been evaluated the population of patients with cirrhosis, test-retest reliability is high in patients without cirrhosis: 0.85 for grip strength, (26) 0.73-0.78 for chair stands, (27) and 0.55-0.75 for balance. (27) Nor did we evaluate inter-and intraobserver variability of the subjective hepatologist's rating of the patient's health, which would be important to further support the construct validity of this index. In addition, this cohort did not include patients in the inpatient setting, limiting the utility of this frailty index to outpatients. We believe that the construct of frailty can play its greatest role for candidates in the outpatient setting, allowing for sufficient time to engage in prehabilitation, to seek faster paths to transplant (e.g., living donor LT, transplant at a center with a lower transplant MELDNa score), or initiate hospice care services. Also potentially limiting the generalizability of this index is the fact that we did not enroll patients aged <60 years if their MELD scores were <12. However, the intended use of this index is for patients with cirrhosis awaiting LT, given that physical frailty likely disproportionately impacts this population because of the cumulative effects of decompensated cirrhosis. Although this may introduce spectrum bias with possible overestimation of the predictive accuracy of the frailty index, we believe that the index was developed on the population for whom it would have the greatest clinical relevance. We excluded patients with severe HE because of concerns about their ability to follow frailty test directions, which also could have introduced further spectrum bias in our results. However, this exclusion criterion applied to only 8 patients (reflecting the outpatient nature of our cohort), so we do not believe that exclusion of these patients significantly impacts our findings. On the other hand, we included 21 patients with refractory ascites who also may have had greater difficulty with performing the frailty tests, but, in this case, we felt that their lower scores would truly reflect their insufficient muscle mass and poor nutritional status, rather than reflect an inability to follow the frailty test instructions. Last, we did not evaluate interclinician variability of the decision to delist a patient for being "too sick for transplant," an outcome not defined by strict criteria. However, as described in a multicenter study evaluating center-level transplant decision making, these decisions are reasonably consistent and based on the consensus that, for medical reasons, they would have poor outcomes despite receiving a transplant. (28) The strength of this study is that it includes a large number of patients who experienced a high number of events over a relatively short period of time, but the data are only from one center. However, this single-center index is the critical first step to synchronize our nation's efforts at capturing the concept of frailty in clinical practice. Several centers have already reported on their use of frailty, as measured by a variety of frailty instruments originally developed in older adults without cirrhosis such as the six-minute walk test, (29) the Braden scale, (30) and the Fried Frailty Index. (31) Beyond the published literature, we know of other centers who have incorporated the timed-up-and-go test or hand grip strength into their evaluations of LT candidates (personal communication). Our frailty index, developed specifically for patients with ESLD, allows us to converge on a relatively parsimonious number of individual tests of physical frailty. Only then will we be positioned to conduct the multicenter studies needed to better understand the impact of frailty on our patients-not just before transplant-but perhaps, even more important, after.
In conclusion, we have developed a simple, easy-toadminister frailty index to predict mortality in patients with ESLD. Our index lays the foundation for future studies to investigate the relationship between frailty and outcomes post-LT, longitudinal changes in frailty over time, as well as develop interventions designed to reverse frailty and improve both survival and quality of life in patients with cirrhosis. 
